Cover
Cover - USD ($) | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 31, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Dec. 31, 2021 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2021 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity File Number | 000-55203 | ||
Entity Registrant Name | eWELLNESS HEALTHCARE CORPORATION | ||
Entity Central Index Key | 0001550020 | ||
Entity Tax Identification Number | 90-1073143 | ||
Entity Incorporation, State or Country Code | NV | ||
Entity Address, Address Line One | 1125 S Federal Hwy #464 | ||
Entity Address, City or Town | Fort Lauderdale | ||
Entity Address, State or Province | FL | ||
Entity Address, Postal Zip Code | 33316 | ||
City Area Code | (855) | ||
Local Phone Number | 470-1700 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 10,624,610 | ||
Entity Common Stock, Shares Outstanding | 18,507,683,627 | ||
Documents incorporated by reference | None | ||
Auditor Firm ID | 457 | ||
Auditor Name | Haynie & Company | ||
Auditor Location | Salt Lake City, Utah |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
CURRENT ASSETS | ||
Cash | $ 11,177 | $ 1,109 |
Prepaid expenses | 3,235 | |
Total current assets | 11,177 | 4,344 |
Property & equipment, net | 2,387 | 3,788 |
TOTAL ASSETS | 13,564 | 8,132 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 1,223,278 | 892,164 |
Accrued expenses - related party | 144,471 | 292,762 |
Accrued compensation | 200,000 | 200,000 |
Loan payable | 1,662 | |
Convertible debt, net of discount | 1,354,882 | 1,354,882 |
Derivative liability | 1,447,008 | 3,925,106 |
Total current liabilities | 4,371,301 | 6,664,914 |
Total Liabilities | 4,371,301 | 6,664,914 |
COMMITMENTS AND CONTINGENCIES | ||
STOCKHOLDERS’ DEFICIT | ||
Common stock, authorized 20,000,000,000 shares, $.001 par value, 18,507,683,627 and 16,862,481,961 issued and outstanding, respectively | 18,507,684 | 16,862,482 |
Shares to be issued | 263 | |
Additional paid in capital | 17,203,420 | 16,097,866 |
Accumulated deficit | (40,069,797) | (39,618,090) |
Total Stockholders’ Deficit | (4,357,737) | (6,656,782) |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | 13,564 | 8,132 |
Series A Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred Stock Value | 697 | 697 |
Series C Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred Stock Value | 92 | |
Series D Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred Stock Value | 20 | |
Series E Preferred Stock [Member] | ||
STOCKHOLDERS’ DEFICIT | ||
Preferred Stock Value | $ 147 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Common stock, shares authorized | 20,000,000,000 | 20,000,000,000 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares issued | 18,507,683,627 | 16,862,481,961 |
Common stock, shares outstanding | 18,507,683,627 | 16,862,481,961 |
Series A Preferred Stock [Member] | ||
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares issued | 696,667 | 696,667 |
Preferred stock, shares outstanding | 696,667 | 696,667 |
Series C Preferred Stock [Member] | ||
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued | 920,000 | 0 |
Preferred stock, shares outstanding | 920,000 | 0 |
Series D Preferred Stock [Member] | ||
Preferred stock, shares authorized | 200,000 | 200,000 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued | 200,000 | 0 |
Preferred stock, shares outstanding | 200,000 | 0 |
Series E Preferred Stock [Member] | ||
Preferred stock, shares authorized | 2,500,000 | 2,500,000 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued | 1,465,680 | 0 |
Preferred stock, shares outstanding | 1,465,680 | 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
REVENUE | ||
Revenue | $ 266,570 | |
Cost of revenue | 11,224 | |
Net Revenue | 255,346 | |
OPERATING EXPENSES | ||
Executive compensation | 260,000 | 767,639 |
General and administrative | 280,177 | 699,440 |
Professional fees | 2,130,850 | 1,180,583 |
Total Operating Expenses | 2,671,027 | 2,647,662 |
Loss from Operations | (2,671,027) | (2,392,316) |
OTHER INCOME (EXPENSE) | ||
Interest income | 1 | |
Gain on extinguishment of debt | 24,738 | |
Gain (loss) on derivative liability | 2,478,098 | (5,441,140) |
Loss on disposal of asset | (8,205) | |
Interest expense | (258,778) | (954,605) |
Net Income (Loss) before Income Taxes | (451,707) | (8,771,527) |
Income tax expense | ||
Net Income (Loss) | $ (451,707) | $ (8,771,527) |
Basic and diluted (loss) per common share | $ 0 | $ 0 |
Weighted average basic and diluted shares outstanding | 17,579,528,194 | 7,849,264,946 |
Reconciliation of Stockholders'
Reconciliation of Stockholders' Deficit - USD ($) | Preferred Stock [Member]Series A Preferred Stock [Member] | Preferred Stock [Member]Series C Preferred Stock [Member] | Preferred Stock [Member]Series D Preferred Stock [Member] | Preferred Stock [Member]Series E Preferred Stock [Member] | Common Stock [Member] | Shares to be Issued [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2019 | $ 250 | $ 12,752 | $ 150 | $ 23,927,374 | $ (30,846,563) | $ (6,906,037) | |||
Balance, shares at Dec. 31, 2019 | 250,000 | 12,752,084 | |||||||
Contributed services | 153,518 | 153,518 | |||||||
Shares issued to officers, directors and consultants | $ 447 | 1,339,553 | 1,340,000 | ||||||
Shares issued to officers, directors and consultants, shares | 446,667 | ||||||||
Shares issued to officers, directors and consultants, shares | |||||||||
Shares issued for debt conversion | $ 16,849,014 | (15,000,597) | 1,848,417 | ||||||
Shares issued for debt conversion, shares | 16,849,013,669 | ||||||||
Shares issued for services | $ 668 | $ 113 | $ 956 | $ 1,737 | |||||
Shares issued for services, shares | 668,332 | ||||||||
Shares issued for rounding - 50:1 split | 48 | (48) | |||||||
Shares issued for rounding - 50:1 split, shares | 47,876 | ||||||||
Discontinued operations | $ 688,595 | $ 688,595 | |||||||
Derivative liability | 4,988,515 | 4,988,515 | |||||||
Net loss | (8,771,527) | (8,771,527) | |||||||
Balance at Dec. 31, 2020 | $ 697 | $ 16,862,482 | 263 | 16,097,866 | (39,618,090) | (6,656,782) | |||
Balance, shares at Dec. 31, 2020 | 696,667 | 16,862,481,961 | |||||||
Shares issued to officers, directors and consultants | $ 92 | $ 20 | $ 128 | 2,399,760 | 2,400,000 | ||||
Shares issued to officers, directors and consultants, shares | 920,000 | 200,000 | 1,280,000 | ||||||
Shares issued for services | $ 2,002 | (263) | (988) | $ 750 | |||||
Shares issued for services, shares | 2,001,666 | 2,001,666 | |||||||
Net loss | (451,707) | $ (451,707) | |||||||
Shares issued for cash | $ 35 | 349,965 | 350,000 | ||||||
Shares issued for cash, shares | 350,000 | ||||||||
Shares issued for conversion | $ (16) | $ 1,643,200 | (1,643,183) | ||||||
Shares issued for conversion, shares | (164,320) | 1,643,200,000 | |||||||
Balance at Dec. 31, 2021 | $ 697 | $ 92 | $ 20 | $ 147 | $ 18,507,684 | $ 17,203,420 | $ (40,069,797) | $ (4,357,737) | |
Balance, shares at Dec. 31, 2021 | 696,667 | 920,000 | 200,000 | 1,465,680 | 18,507,683,627 |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities | ||
Net income (loss) | $ (451,707) | $ (8,771,527) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
Depreciation and amortization | 1,402 | 6,869 |
Contributed services | 153,518 | |
Shares issued to officers, directors and consultants | 1,120,000 | 503,588 |
Shares issued for consulting services | 1,280,750 | 1,737 |
Shares issued for financing costs | 95,933 | |
Gain on extinguishment of debt | (1,556) | |
Amortization of debt discount and prepaids | 795,591 | |
(Gain) loss on derivative liability | (2,478,098) | 5,441,140 |
Loss on disposal of asset | 8,205 | |
Changes in operating assets and liabilities | ||
Prepaid expense | 3,235 | (21,887) |
Accounts receivable | (66,848) | |
Accounts payable and accrued expenses | 331,115 | 919,981 |
Accounts payable - related party | 160,460 | |
Accrued expenses - related party | (148,291) | 29,995 |
Accrued compensation | 460,188 | |
Net cash used in operating activities | (341,594) | (284,613) |
Cash flows from financing activities | ||
Proceeds from issuance of convertible debt | 52,800 | |
Original issue discount and debt issuance costs | (7,800) | |
Loan payable | 1,662 | |
Proceeds from issuance of preferred series E | 350,000 | |
Net cash provided by financing activities | 351,662 | 45,000 |
Net increase (decrease) in cash | 10,068 | (239,613) |
Cash, beginning of period | 1,109 | 240,722 |
Cash, end of period | 11,177 | 1,109 |
Cash paid for: | ||
Taxes | ||
Interest Expense | ||
Non-cash items: | ||
Shares issued for debt conversion | $ 1,848,417 |
The Company
The Company | 12 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
The Company | Note 1. The Company The Company, Background and Nature of Business eWellness Healthcare Corporation (the “eWellness”, “Company”, “we”, “us”, “our”) was incorporated in the State of Nevada on April 7, 2011. eWellness Healthcare Corporation is the first physical therapy telehealth company to offer real-time distance monitored assessments and treatments. On September 15, 2020, the Company and Bistromatics signed an agreement that transferred all worldwide marketing and Intellectual Property Rights or claims to the Company’s Phzio, Phzio TeleRehab and MSK 360 platforms to Bistromatics in return for a 15 748,832 During the last quarter of 2020 and the first quarter of 2021, the Company’s Board of Directors and management determined that while it would continue its efforts and resources involving physical therapy and telemedicine, it would also pursue other health-related business opportunities. With the Company’s announced plan to diversify its health-related business beyond its telemedicine operations, which telemedicine operations will continue, the Company on May 18, 2021, entered into an Agreement and Plan of Merger by and between the Company, EWLL Acquisition (a new wholly owned subsidiary of the Company) and a recently formed private Nevada company controlled by a third party, American Health Protection, Inc.(“AMHP”). pursuant to which AMHP merged with EWLL Acquisition, with AMHP being the surviving entity and becoming a wholly owned subsidiary of the Company. On July 14, 2021, the Company filed the requisite Articles of Merger with the State of Nevada and, as a result, AMHP became a wholly owned subsidiary of the Company and EWLL Acquisition ceased to exist. On April 19, 2021, the Company filed a DEF 14C to disclose to the stockholders the ratification and approval by Joint Written Consent, based upon the unanimous approval by our Board of Directors and the consent of the Majority Consenting Stockholders, of the corporate actions to file an amendment to its Amended and Restated Articles of Incorporation to: (i) change the name of the Company from eWellness Healthcare Corporation to American Health Protection Corp. (“Name Change”); (ii) change the par value of the Company’s common stock and preferred stock from $ 0.001 0.0001 implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed As stated in the DEF 14C, the Name Change from eWellness Healthcare Corporation to American Health Protection Corp. was to reflect the Company’s plan to diversify its business operations from the telemedicine business and the proprietary PHZIO System to include other health related services to its primary target market focused on small and mid-sized corporate clients. The Par Value Change of the Company’s Common Stock and Preferred Stock from $ 0.001 0.0001 Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments. Going Concern For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $ 40,069,797 4,360,124 Fair Value of Financial Instruments The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, The guidance also establishes a fair value hierarchy for measurements of fair value as follows: Level 1 – quoted market prices in active markets for identical assets or liabilities. Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Summary of Assets and Liabilities Fair Value on Recurring Basis Total Level 1 Level 2 Level 3 Derivative Liability $ 1,447,008 $ - $ - $ 1,447,008 Total Liabilities measured at fair value $ 1,447,008 $ - $ - $ 1,447,008 As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ - $ - $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106 Revenue Recognition The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed. Property and Equipment Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows: Schedule of Estimated Useful Lives for Significant Property and Equipment Furniture and Fixtures 5 7 Computer Equipment 5 7 Software 3 The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized. Intangible Assets The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets. Income Taxes The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized. Debt Issuance Costs The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets. Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.” Cash and Cash Equivalents Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. Loss per Common Share The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Options - 27,000 Warrants - 26,015 Convertible Notes 12,357,170,485 24,728,206,940 Total 12,357,170,485 27,728,259,955 Recent Accounting Pronouncements The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results. |
Property and Equipment
Property and Equipment | 12 Months Ended |
Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | Note 3. Property and Equipment Property and equipment consist of computer equipment that is stated at cost $ 6,976 and $ 6,976 less accumulated depreciation of $ 4,589 and $ 3,188 for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2020, the Company disposed of computers with a cost value of $ 11,498 and transferred computers and equipment valued at $ 9,208 per the Bistromatics agreement dated September 15, 2020. (Footnote 1). Depreciation expense was $ 1,402 and $ 4,869 for the years ended December 31, 2021 and 2020, respectively. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Note 4. Intangible Assets The Company recognizes the cost of a software license and a license for use of a programming code as intangible assets. The stated cost of these assets and accumulated amortization were transferred per the Bistromatics agreement dated September 15, 2020 (Footnote 1). For the years ended December 31, 2021 and 2020, the amortization expense recorded was $ 0 2,000 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 5. Income Taxes Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020: Schedule of Deferred Tax Liabilities 2021 2020 Deferred tax assets: NOL carryover $ 4,027,300 $ 4,133,200 Accrued payroll 42,000 42,000 Deferred tax liabilities Depreciation 400 300 Valuation allowance (4,069,700 ) (4,175,500 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following: Schedule of Pre-tax from Continuing Operations 2020 2019 Book loss $ (94,900 ) $ (1,842,000 ) Depreciation - 700 Contributed services 504,000 32,200 Meals & entertainment 2,600 2,400 Stock for prepaids 700 36,900 Stock for consulting 200 400 Amortization of debt discount - 130,200 Accrued payroll - (69,900 ) Gain on debt extinguishment - (5,200 ) Related party accruals - (123,100 ) Loss on disposal - 1,700 Derivative (Gain)/Loss (520,400 ) 114,260 Valuation allowance 107,800 693,100 Income tax expense benefit $ - $ - As of December 31, 2021, the Company had net operating loss carry forwards of approximately $ 19,177,000 that may be offset against future taxable income from the year 2022 through 2041 . No tax benefit has been reported in the December 31, 2020 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2021 and 2020, the Company did not recognize any interest or penalties, nor did we have any interest or penalties accrued related to unrecognized benefits. The tax years ended December 31, 2021, 2020 and 2019 are open for examination for federal income tax purposes and by other major taxing jurisdictions to which we are subject. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 6. Related Party Transactions Throughout the year ended December 31, 2021, the officers and directors of the Company incurred business expenses on behalf of the Company. The amounts payable to the officers as of the years ended December 31, 2021 and 2020 were $ 33,701 11,655 221,107 221,107 100,000 100,000 200,000 200,000 |
Convertible Notes Payable
Convertible Notes Payable | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Convertible Notes Payable | Note 7. Convertible Notes Payable Year Ended December 31, 2021 During the year ended December 31, 2021, there were no new convertible notes executed. During the year ended December 31, 2021, the Company accrued interest payable of $ 258,778 Year Ended December 31, 2020 In March 2020, the Company executed a 12 52,800 January 15, 2021 4,800 3,000 70 10 2,880 During the year ended December 31, 2020, the Company accrued interest of $ 330,871 |
Equity Transactions
Equity Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Equity Transactions | Note 8. Equity Transactions Preferred Stock The total number of shares of Series A Preferred Stock which the Company shall have authority to issue is 20,000,000 0.001 1,000,000 The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance 3,000,000 In April 2021, the Board of Directors issued a Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock. The Board authorized that the Company shall have the authority to issue 1,000,000 .0001 In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights Limitations of Series D Preferred Stock. The Board authorized that the Company shall have the authority to issue 200,000 .0001 In April 2021, the Board of Directors issued a Certificate of Designations, Preferences and Rights of Series E Convertible Preferred Stock. The Board authorized that the Company shall have authority to issue 2,500,000 .0001 1.00 The Series C, Series D and Series E Preferred Stock will rank, with respect to rights to the payment of dividends and the distribution of assets in the event of any liquidation, dissolution or winding up of the Corporation, (i) senior to all classes or series of the Corporation’s Common Stock, par value $0.001 per share (“Common Stock”), and to all other equity securities issued by the Corporation ; and (ii) effectively junior to all existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) of the Corporation and to any indebtedness and other liabilities of (as well as any preferred equity interest held by others) existing subsidiaries of the Corporation. The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time . On May 4, 2021, the Board of Directors issued 350,000 1.00 On May 12, 2021, the Board of Directors authorized the issuance of 200,000 200,000 On May 20, 2021, the Board of Directors authorized the issuance of 920,000 920,000 On July 1, 2021, the Board of Directors authorized the issuance of 1,280,000 1,280,000 July 14, 2021 Common Stock On February 12, 2020, FINRA approved a 1:50 reverse split 1:50 reverse split 47,876 On February 14, 2020, the Company filed a Definitive Information Statement on Schedule 14C for the purpose of authorizing the increase in the number of authorized shares of Common Stock from one billion nine hundred million ( 1,900,000,000 20,000,000,000 Debt Conversion Shares 2021 During the year ended December 31, 2021, there were no shares of common stock issued for debt conversion. 2020 During the year ended December 31, 2020, the Company issued a total of 16,849,013,669 1,607,317 145,167 95,933 Consultant Issued Shares 2021 During the year ended December 31, 2021, the Company issued 2,001,666 750 2020 On January 30, 2020, the Company executed a 12-month advisory services agreement. The Company is to issue 20,000 80,000 103 160,000 30 2,500 During the year ended December 31, 2020, the Company issued 588,332 1,604 Preferred Series E Conversion 2021 During the year ended December 31, 2021, the Company issued 1,643,200,000 164,320 164,320 2020 None Stock Options The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively: Summary of Stock Options Activity Number Weighted of Stock Average Remaining Intrinsic Options Exercise Price Life (yrs.) Value Outstanding on January 1, 2020 57,000 $ 40.00 1.1 $ - Granted - - - - Exercised - - - - Expired/cancelled (30,000 ) 40.00 .14 - Outstanding on December 31, 2020 27,000 $ 40.00 .14 $ - Granted - - - - Exercised - - - - Expired/cancelled (27,000 ) - - - Outstanding on December 31, 2021 - - - $ - Options exercisable on December 31, 2021 - $ - - $ - Warrants The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively: Summary of Warrants Activity Weighted Number of Average Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding on January 1, 2020 42,015 $ 12.00 1.9 $ 0.037 Granted - - - - Exercised - - - - Cancelled (16,000 ) 11.04 - - Outstanding on December 31, 2020 26,015 $ 12.50 1.2 $ - Granted - - - - Exercised - - - - Cancelled (26,015 ) - - - Outstanding on December 31, 2021 - $ - - $ - Warrants exercisable on December 31, 2021 - $ - - $ - |
Commitments, Contingencies
Commitments, Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments, Contingencies | Note 9. Commitments, Contingencies The Company may be subject to lawsuits, administrative proceedings, regulatory reviews or investigations associated with its business and other matters arising in the normal conduct of its business. On August 12, 2020, a former consultant filed suit in the Superior Court of the State of California for Breach of Contract and non-payment of fees per said contract. At the time of the suit, the Company owed to the vendor for contractual fees the total of $ 24,339 $38,000 5,000 5,000 38,000 |
Revenue Recognition
Revenue Recognition | 12 Months Ended |
Dec. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenue Recognition | Note 10. Revenue Recognition Under ASC Topic 606, the Company recognizes revenue when the services have been completed. During the years ended December 31, 2021 and 2020, the Company recognized net revenue of $ 0 255,346 |
Derivative Valuation
Derivative Valuation | 12 Months Ended |
Dec. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Valuation | Note 11. Derivative Valuation The Company evaluated the convertible debentures and associated warrants in accordance with ASC Topic 815, “Derivatives and Hedging,” and determined that the conversion feature of the convertible promissory notes was not afforded the exemption for conventional convertible instruments due to their variable conversion rates. The notes have no explicit limit on the number of shares issuable, so they did not meet the conditions set forth in current accounting standards for equity classification. In addition, the warrants have a Most Favoured Nations clause resulting in the exercise price of the warrants also not being fixed. Therefore, these have been characterized as derivative instruments. We elected to recognize the notes under ASU paragraph 815-15-25-4, whereby there would be a separation into a host contract and derivative instrument. We elected to initially and subsequently measure the notes and warrants in their entirety at fair value, with changes in fair value recognized in earnings. The debt discount is amortized over the life of the note and recognized as interest expense. For the years ended December 31, 2021 and 2020, the Company amortized the debt discount of $ 0 619,799 During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account: Schedule of Derivative Liability Notes Warrants Total Derivative liability at January 1, 2020 $ 3,529,967 $ 7 $ 3,529,974 Addition of new conversion 47,620 - 47,620 Conversion of note derivatives (5,094,792 ) - (5,094,792 ) Change in fair value 5,442,306 (2 ) 5,442,304 Derivative liability at December 31, 2020 $ 3,925,101 $ 5 $ 3,925,106 Change in fair value (2,478,093 ) (5 ) (2,478,098 ) Derivative liability at December 31, 2020 $ 1,447,008 $ - $ 1,447,008 For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow: Schedule of Assumptions Used Black Scholes Valuation of Derivative Stock price at valuation date $ .0002 Risk free interest rate .06 % Stock volatility factor 350.10 % Years to Maturity .08 Expected dividend yield None |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 12 Months Ended |
Dec. 31, 2021 | |
Supplemental Cash Flow Elements [Abstract] | |
Supplemental Cash Flow Information | Note 12. Supplemental Cash Flow Information During the year ended December 31, 2021, the Company had the following cash and non-cash investing and financing activities: ● Issued 350,000 350,000 ● Issued 1,643,200,000 163,400 163,400 ● Issued 2,001,666 750 During the year ended December 31, 2020, the Company had the following non-cash investing and financing activities: ● Issued 16,849,013,669 1,607,317 145,167 95,933 ● Issued 668,332 1,737 |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 13. Subsequent Events On March 14, 2022, the Company accepted a Stipulation and Proposed Order for the payment of $ 38,000 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these good faith estimates and judgments. |
Going Concern | Going Concern For the year ended December 31, 2021, the Company had no revenues. The Company has an accumulated deficit of $ 40,069,797 4,360,124 |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company complies with the accounting guidance under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10, Fair Value Measurements, The guidance also establishes a fair value hierarchy for measurements of fair value as follows: Level 1 – quoted market prices in active markets for identical assets or liabilities. Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Summary of Assets and Liabilities Fair Value on Recurring Basis Total Level 1 Level 2 Level 3 Derivative Liability $ 1,447,008 $ - $ - $ 1,447,008 Total Liabilities measured at fair value $ 1,447,008 $ - $ - $ 1,447,008 As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ - $ - $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106 |
Revenue Recognition | Revenue Recognition The Company recognizes revenue per ASC 606. Revenue is recognized when services have been completed. |
Property and Equipment | Property and Equipment Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows: Schedule of Estimated Useful Lives for Significant Property and Equipment Furniture and Fixtures 5 7 Computer Equipment 5 7 Software 3 The Company regularly evaluates whether events or circumstances have occurred that indicate the carrying value of long-lived assets may not be recoverable. If factors indicate the asset may not be recoverable, we compare the related undiscounted future net cash flows to the carrying value of the asset to determine if impairment exists. If the expected future net cash flows are less than the carrying value, an impairment charge is recognized based on the fair value of the asset. For the years ended December 31, 2021 and 2020, there was no impairment recognized. |
Intangible Assets | Intangible Assets The Company accounts for assets that are not physical in nature as intangible assets. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. Intangible assets with indefinite useful lives are reassessed each year for impairment. If an impairment has occurred, then a loss is recognized. An impairment loss is determined by subtracting the asset’s fair value from the asset’s book/carrying value. For the years ended December 31, 2021 and 2020, there were no intangible assets. |
Income Taxes | Income Taxes The Company accounts for income taxes under FASB ASC 740-10-30. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all the benefits of deferred tax assets will not be realized. |
Debt Issuance Costs | Debt Issuance Costs The Company accounts for debt issuance costs in accordance with ASU 2015-03. This guidance requires direct and incremental costs associated with the issuance of debt instruments such as legal fees, printing costs and underwriters’ fees, among others, paid to parties other than creditors, are reported and presented as a reduction of debt on the consolidated balance sheets. Debt issuance costs and premiums or discounts are amortized over the term of the respective financing arrangement using the effective interest method. Amortization of these amounts is included as a component of interest expense net, in the consolidated statements of operations. |
Derivative Financial Instruments | Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and then is revalued at each reporting date, with changes in fair value reported in the statement of operations. For stock based derivative financial instruments, Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once determined, derivative liabilities are adjusted to reflect fair value at the end of each reporting period. Any increase or decrease in the fair value from inception is made quarterly and appears in results of operations as a change in fair market value of derivative liabilities.” |
Cash and Cash Equivalents | Cash and Cash Equivalents Cash and cash equivalents include all cash deposits and highly liquid financial instruments with an original maturity to the Company of three months or less. The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. |
Loss per Common Share | Loss per Common Share The Company follows ASC Topic 260 to account for the loss per share. Basic loss per common share calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share calculations are determined by dividing net loss by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. As the Company has incurred losses for the periods ended December 31, 2021 and 2020, no dilutive shares are added into the loss per share calculations. While currently antidilutive, the following instruments could potentially dilute EPS in the future resulting in the following common stock equivalents: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Options - 27,000 Warrants - 26,015 Convertible Notes 12,357,170,485 24,728,206,940 Total 12,357,170,485 27,728,259,955 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. |
Reclassifications | Reclassifications Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Summary of Assets and Liabilities Fair Value on Recurring Basis | As of December 31, 2021, the Company had the following assets and liabilities measured at fair value on a recurring basis. Summary of Assets and Liabilities Fair Value on Recurring Basis Total Level 1 Level 2 Level 3 Derivative Liability $ 1,447,008 $ - $ - $ 1,447,008 Total Liabilities measured at fair value $ 1,447,008 $ - $ - $ 1,447,008 As of December 31, 2020, the Company had the following assets and liabilities measured at fair value on a recurring basis. Total Level 1 Level 2 Level 3 Derivative Liability $ 3,925,106 $ - $ - $ 3,925,106 Total Liabilities measured at fair value $ 3,925,106 $ - $ - $ 3,925,106 |
Schedule of Estimated Useful Lives for Significant Property and Equipment | Property and equipment are recorded at historical cost. Minor additions and renewals are expensed in the year incurred. Major additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The estimated useful lives for significant property and equipment categories are as follows: Schedule of Estimated Useful Lives for Significant Property and Equipment Furniture and Fixtures 5 7 Computer Equipment 5 7 Software 3 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 Options - 27,000 Warrants - 26,015 Convertible Notes 12,357,170,485 24,728,206,940 Total 12,357,170,485 27,728,259,955 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Deferred Tax Liabilities | Net deferred tax liabilities consist of the following components as of December 31, 2021 and 2020: Schedule of Deferred Tax Liabilities 2021 2020 Deferred tax assets: NOL carryover $ 4,027,300 $ 4,133,200 Accrued payroll 42,000 42,000 Deferred tax liabilities Depreciation 400 300 Valuation allowance (4,069,700 ) (4,175,500 ) Net deferred tax asset $ - $ - |
Schedule of Pre-tax from Continuing Operations | The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pre-tax income from continuing operations for the years ended December 31, 2021 and 2020 due to the following: Schedule of Pre-tax from Continuing Operations 2020 2019 Book loss $ (94,900 ) $ (1,842,000 ) Depreciation - 700 Contributed services 504,000 32,200 Meals & entertainment 2,600 2,400 Stock for prepaids 700 36,900 Stock for consulting 200 400 Amortization of debt discount - 130,200 Accrued payroll - (69,900 ) Gain on debt extinguishment - (5,200 ) Related party accruals - (123,100 ) Loss on disposal - 1,700 Derivative (Gain)/Loss (520,400 ) 114,260 Valuation allowance 107,800 693,100 Income tax expense benefit $ - $ - |
Equity Transactions (Tables)
Equity Transactions (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Summary of Stock Options Activity | The following is a summary of the status of all Company’s stock options as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively: Summary of Stock Options Activity Number Weighted of Stock Average Remaining Intrinsic Options Exercise Price Life (yrs.) Value Outstanding on January 1, 2020 57,000 $ 40.00 1.1 $ - Granted - - - - Exercised - - - - Expired/cancelled (30,000 ) 40.00 .14 - Outstanding on December 31, 2020 27,000 $ 40.00 .14 $ - Granted - - - - Exercised - - - - Expired/cancelled (27,000 ) - - - Outstanding on December 31, 2021 - - - $ - Options exercisable on December 31, 2021 - $ - - $ - |
Summary of Warrants Activity | The following is a summary of the status of the Company’s warrants as of December 31, 2021 and changes during the periods ended on December 31, 2021 and 2020, respectively: Summary of Warrants Activity Weighted Number of Average Remaining Intrinsic Warrants Price Life (yrs.) Value Outstanding on January 1, 2020 42,015 $ 12.00 1.9 $ 0.037 Granted - - - - Exercised - - - - Cancelled (16,000 ) 11.04 - - Outstanding on December 31, 2020 26,015 $ 12.50 1.2 $ - Granted - - - - Exercised - - - - Cancelled (26,015 ) - - - Outstanding on December 31, 2021 - $ - - $ - Warrants exercisable on December 31, 2021 - $ - - $ - |
Derivative Valuation (Tables)
Derivative Valuation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Derivative Liability | During the years ended December 31, 2021 and 2020, the Company had the following activity in the derivative liability account: Schedule of Derivative Liability Notes Warrants Total Derivative liability at January 1, 2020 $ 3,529,967 $ 7 $ 3,529,974 Addition of new conversion 47,620 - 47,620 Conversion of note derivatives (5,094,792 ) - (5,094,792 ) Change in fair value 5,442,306 (2 ) 5,442,304 Derivative liability at December 31, 2020 $ 3,925,101 $ 5 $ 3,925,106 Change in fair value (2,478,093 ) (5 ) (2,478,098 ) Derivative liability at December 31, 2020 $ 1,447,008 $ - $ 1,447,008 |
Schedule of Assumptions Used Black Scholes Valuation of Derivative | For purposes of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative are as follow: Schedule of Assumptions Used Black Scholes Valuation of Derivative Stock price at valuation date $ .0002 Risk free interest rate .06 % Stock volatility factor 350.10 % Years to Maturity .08 Expected dividend yield None |
The Company (Details Narrative)
The Company (Details Narrative) - USD ($) | Apr. 19, 2021 | Sep. 15, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Apr. 18, 2021 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Professional Fees | $ 2,130,850 | $ 1,180,583 | |||
Common stock par value | $ 0.0001 | $ 0.001 | $ 0.001 | $ 0.001 | |
Preferred stock par value | $ 0.0001 | $ 0.001 | |||
Reverse Stock Split | implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed | ||||
Description of change in par value | Common Stock on the OTC Markets had been less than the $0.001 par value of its Common Stock. As a result, the Company had not been able to raise capital by the issuance of shares of Common Stock at less than the $0.001 par value and, in addition, the Company could not raise capital through the issuance of shares of convertible Preferred Stock having a conversion price of less than the $0.001 par value of the Common Stock. | ||||
Services Agreement [Member] | Bistromatics Inc. [Member] | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Equity Method Investment, Ownership Percentage | 15.00% | ||||
Professional Fees | $ 748,832 |
Summary of Assets and Liabiliti
Summary of Assets and Liabilities Fair Value on Recurring Basis (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative Liability | $ 1,447,008 | $ 3,925,106 |
Total Liabilities measured at fair value | 1,447,008 | 3,925,106 |
Fair Value, Inputs, Level 1 [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative Liability | ||
Total Liabilities measured at fair value | ||
Fair Value, Inputs, Level 2 [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative Liability | ||
Total Liabilities measured at fair value | ||
Fair Value, Inputs, Level 3 [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative Liability | 1,447,008 | 3,925,106 |
Total Liabilities measured at fair value | $ 1,447,008 | $ 3,925,106 |
Schedule of Estimated Useful Li
Schedule of Estimated Useful Lives for Significant Property and Equipment (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Furniture and Fixtures [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Furniture and Fixtures [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 7 years |
Computer Equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Computer Equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 7 years |
Software Development [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 3 years |
Schedule of Antidilutive Securi
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive potential earnings per share, amount | 12,357,170,485 | 27,728,259,955 |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive potential earnings per share, amount | 27,000 | |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive potential earnings per share, amount | 26,015 | |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive potential earnings per share, amount | 12,357,170,485 | 24,728,206,940 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Accounting Policies [Abstract] | ||
Accumulated loss | $ 40,069,797 | $ 39,618,090 |
Working capital deficit | $ 4,360,124 |
Property and Equipment (Details
Property and Equipment (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Abstract] | ||
Property, Plant and Equipment, Gross | $ 6,976 | $ 6,976 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 4,589 | 3,188 |
Impairment of Long-Lived Assets to be Disposed of | 11,498 | |
Transferred computers and equipment | 9,208 | |
Depreciation | $ 1,402 | $ 4,869 |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization of Intangible Assets | $ 0 | $ 2,000 |
Schedule of Deferred Tax Liabil
Schedule of Deferred Tax Liabilities (Details) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 |
Income Tax Disclosure [Abstract] | ||
NOL carryover | $ 4,027,300 | $ 4,133,200 |
Accrued payroll | 42,000 | 42,000 |
Depreciation | 400 | 300 |
Valuation allowance | (4,069,700) | (4,175,500) |
Net deferred tax asset |
Schedule of Pre-tax from Contin
Schedule of Pre-tax from Continuing Operations (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | ||
Book loss | $ (94,900) | $ (1,842,000) |
Depreciation | 700 | |
Contributed services | 504,000 | 32,200 |
Meals & entertainment | 2,600 | 2,400 |
Stock for prepaids | 700 | 36,900 |
Stock for consulting | 200 | 400 |
Amortization of debt discount | 130,200 | |
Accrued payroll | (69,900) | |
Gain on debt extinguishment | (5,200) | |
Related party accruals | (123,100) | |
Loss on disposal | 1,700 | |
Derivative (Gain)/Loss | (520,400) | 114,260 |
Valuation allowance | 107,800 | 693,100 |
Income tax expense benefit |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Income Tax Disclosure [Abstract] | |
Operating Loss Carryforwards | $ 19,177,000 |
Income taxable description | 2022 through 2041 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 |
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | |||
Accrued director's fees | $ 221,107 | $ 221,107 | |
Accrued executive compensation | 200,000 | 200,000 | |
Settlement and compromise agreement [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | |||
Accrued director's fees | $ 100,000 | ||
Officers and Directors [Member] | |||
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] | |||
Due to related parties, current | $ 33,701 | $ 11,655 |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details Narrative) | 1 Months Ended | ||
Mar. 31, 2020USD ($)Trading | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | |
Short-term Debt [Line Items] | |||
Accrued interest | $ 145,167 | ||
Convertible Notes Payable [Member] | |||
Short-term Debt [Line Items] | |||
Accrued interest | $ 258,778 | ||
12% Convertible Promissory Note [Member] | |||
Short-term Debt [Line Items] | |||
Accrued interest | 2,880 | ||
Debt interest stated rate | 12.00% | ||
Debt Instrument, principal amount | $ 52,800 | ||
Debt instrument maturity date | Jan. 15, 2021 | ||
Original issue discount | $ 4,800 | ||
Transaction costs | $ 3,000 | ||
Convertible debt percentage | 70.00% | ||
Number of trading days | Trading | 10 | ||
2019 Convertible Notes [Member] | |||
Short-term Debt [Line Items] | |||
Accrued interest | $ 330,871 |
Summary of Stock Options Activi
Summary of Stock Options Activity (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||
Number of Stock Options Outstanding, Beginning Balance | 27,000 | 57,000 |
Weighted Average Exercise Price Outstanding, Beginning Balance | $ 40 | $ 40 |
Remaining Life (yrs) Outstanding, Beginning Balance | 1 month 20 days | 1 year 1 month 6 days |
Intrinsic Value Outstanding, Beginning Balance | ||
Number of Stock Options Outstanding, Granted | ||
Weighted Average Exercise Price, Granted | ||
Number of Stock Options Outstanding, Exercised | ||
Weighted Average Exercise Price, Exercised | ||
Number of Stock Options Outstanding, Cancelled | (27,000) | (30,000) |
Weighted Average Exercise Price Outstanding,Ending Balance | $ 40 | |
Remaining Life (yrs) expired/ cancelled | 1 month 20 days | |
Number of Warrants, Outstanding, Ending Balance | 26,015 | |
Remaining Life (yrs) Outstanding, Ending Balance | ||
Intrinsic Value Options exercisable, Ending Balance | ||
Number of Stock Options exercisable, Ending Balance | ||
Weighted Average Exercise Price Options exercisable, Ending Balance | ||
Remaining Life (yrs) Outstanding, Ending Balance | ||
Intrinsic Value Options exercisable, Ending Balance |
Summary of Warrants Activity (D
Summary of Warrants Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||
Number of Warrants, Outstanding, Beginning Balance | 26,015 | 42,015 |
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance | $ 12.50 | $ 12 |
Remaining Life (yrs.) Warrants Outstanding, Beginning Balance | 1 year 2 months 12 days | 1 year 10 months 24 days |
Intrinsic Value, Warrants Outstanding, Beginning Balance | $ 0.037 | |
Number of Warrants, Granted | ||
Weighted Average Exercise Price, Granted | ||
Number of Warrants, Exercised | ||
Weighted Average Exercise Price, Exercised | ||
Number of Warrants, Cancelled | (26,015) | (16,000) |
Weighted Average Exercise Price, Cancelled | $ 11.04 | |
Number of Warrants, Outstanding, Ending Balance | 26,015 | |
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance | $ 12.50 | |
Remaining Life (yrs.) Warrants Outstanding, Ending Balance | ||
Intrinsic Value, Warrants Outstanding, Ending Balance | ||
Number of Warrants, exercisable, Ending balance | ||
Weighted Average Exercise Price Exercisable, Ending Balance | ||
Remaining Life (yrs.) Warrants Exercisable, Ending Balance | ||
Intrinsic Value, Warrants Outstanding, Exercisable |
Equity Transactions (Details Na
Equity Transactions (Details Narrative) - USD ($) | May 04, 2021 | Feb. 12, 2020 | Jan. 30, 2020 | Jan. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jul. 01, 2021 | May 20, 2021 | May 12, 2021 | Apr. 30, 2021 | Apr. 19, 2021 | Apr. 18, 2021 | Feb. 14, 2020 |
Class of Stock [Line Items] | ||||||||||||||
Preferred stock par value | $ 0.0001 | $ 0.001 | ||||||||||||
Deferred compensation | $ 3,000,000 | |||||||||||||
Preferred Stock, Voting Rights | The term “equity securities” shall not include convertible debt securities. The Holders of the Series D Preferred Stock have the right, on all matters subject to the vote of the capital stock of the Corporation, to have the collective vote equal to 70% of the total of all voting capital stock of the Corporation, notwithstanding the number of shares of voting capital stock, including shares of common stock, that may be outstanding from time to time | |||||||||||||
Shares issued during period shares | 20,000 | |||||||||||||
Reverse stock split, description | implement the 1:2,000 reverse split of our Common Stock and the shares underlying conversion of the Company’s securities convertible into Common Stock together with the shares reserved for such conversions, on a one for two thousand (1:2,000) basis (“Reverse Split”). The Name Change, Par Value Change and Reverse Split are sometimes referred to as the “Corporate Actions”, which Corporate Actions must be approved by FINRA. The application for approval of these actions to FINRA has not yet been filed | |||||||||||||
Common stock, shares authorized | 20,000,000,000 | 20,000,000,000 | ||||||||||||
Shares issued for debt conversion,shares | 16,849,013,669 | |||||||||||||
Financing cost | $ 95,933 | |||||||||||||
Shares issued during period for services,shares | 2,001,666 | |||||||||||||
Shares issued during period for services, value | $ 750 | 1,737 | ||||||||||||
Stock issued during the period, value | 350,000 | |||||||||||||
Monthly base fee | $ 2,500 | |||||||||||||
Shares issued during period for conversion, value | ||||||||||||||
12- month Advisory Services Agreement [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period shares | 80,000 | |||||||||||||
Stock issued during the period, value | $ 103 | |||||||||||||
Number of sharesto be issued | 160,000 | |||||||||||||
Number of sharesto be issued, value | 30 | |||||||||||||
Convertible Notes [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued for debt conversion,shares | 16,849,013,669 | |||||||||||||
Principal amount | $ 1,607,317 | |||||||||||||
Accrued interest | 145,167 | |||||||||||||
Financing cost | $ 95,933 | |||||||||||||
Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Conversion of stock, description | The shares are eligible for conversion after 24 months into 40 shares of common stock per each preferred share. The value of the issued shares was calculated on the basis of 40 shares per preferred share at the common share value on the date of issuance | |||||||||||||
Common Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Common stock, shares authorized | 20,000,000,000 | 1,900,000,000 | ||||||||||||
Shares issued during period for services,shares | 2,001,666 | 668,332 | ||||||||||||
Shares issued during period for services, value | $ 2,002 | $ 668 | ||||||||||||
Stock issued during the period, value | ||||||||||||||
Conversion of Stock, Shares Converted | 1,643,200,000 | |||||||||||||
Shares issued during period for conversion, value | $ 1,643,200 | |||||||||||||
Officers, Directors and Consultants [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 1,000,000 | |||||||||||||
Board of Directors [Member] | Common Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period shares | 47,876 | |||||||||||||
Reverse stock split, description | 1:50 reverse split | 1:50 reverse split | ||||||||||||
Consultant [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period for services,shares | 588,332 | |||||||||||||
Shares issued during period for services, value | $ 1,604 | |||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 20,000,000 | 20,000,000 | ||||||||||||
Preferred stock par value | $ 0.001 | $ 0.001 | ||||||||||||
Preferred stock value | $ 697 | $ 697 | ||||||||||||
Series A Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period for services, value | ||||||||||||||
Stock issued during the period, value | ||||||||||||||
Shares issued during period for conversion, value | ||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 1,000,000 | 1,000,000 | ||||||||||||
Preferred stock par value | $ 0.0001 | $ 0.0001 | ||||||||||||
Preferred stock value | $ 92 | |||||||||||||
Series C Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period for services, value | ||||||||||||||
Stock issued during the period, value | ||||||||||||||
Shares issued during period for conversion, value | ||||||||||||||
Series C Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 1,000,000 | |||||||||||||
Preferred stock par value | $ 0.0001 | |||||||||||||
Series D Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 200,000 | 200,000 | ||||||||||||
Preferred stock par value | $ 0.0001 | $ 0.0001 | ||||||||||||
Preferred stock value | $ 20 | |||||||||||||
Series D Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period for services, value | ||||||||||||||
Stock issued during the period, value | ||||||||||||||
Shares issued during period for conversion, value | ||||||||||||||
Series D Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 200,000 | |||||||||||||
Preferred stock par value | $ 0.0001 | |||||||||||||
Series E Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 2,500,000 | 2,500,000 | ||||||||||||
Preferred stock par value | $ 0.0001 | $ 0.0001 | ||||||||||||
Preferred stock value | $ 147 | |||||||||||||
Series E Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period shares | 350,000 | |||||||||||||
Shares issued during period for services, value | ||||||||||||||
Stock issued during the period, value | $ 35 | |||||||||||||
Conversion of Stock, Shares Converted | (164,320) | |||||||||||||
Shares issued during period for conversion, value | $ (16) | |||||||||||||
Series E Preferred Stock [Member] | Board of Directors [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 2,500,000 | |||||||||||||
Preferred stock par value | $ 0.0001 | |||||||||||||
Offering price per share | $ 1 | |||||||||||||
Series E Convertible Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 1,280,000 | |||||||||||||
Offering price per share | $ 1 | |||||||||||||
Shares issued during period shares | 350,000 | |||||||||||||
Preferred stock value | $ 1,280,000 | |||||||||||||
Shares issued date | Jul. 14, 2021 | |||||||||||||
Series D Voting Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 200,000 | |||||||||||||
Preferred stock value | $ 200,000 | |||||||||||||
Series C Convertible Preferred Stock [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Preferred stock, shares authorized | 920,000 | |||||||||||||
Preferred stock value | $ 920,000 | |||||||||||||
Preferred Series E Conversion [Member] | ||||||||||||||
Class of Stock [Line Items] | ||||||||||||||
Shares issued during period shares | 1,643,200,000 | |||||||||||||
Conversion of Stock, Shares Converted | 164,320 | |||||||||||||
Shares issued during period for conversion, value | $ 164,320 |
Commitments, Contingencies (Det
Commitments, Contingencies (Details Narrative) - USD ($) | Mar. 14, 2022 | Aug. 12, 2020 |
Former Consultant [Member] | Subsequent Event [Member] | ||
Payment of plaintiffs | $ 38,000 | |
First Payment [Member] | Subsequent Event [Member] | ||
Payment of plaintiffs | 5,000 | |
Every Sixty Days Thereafter [Member] | Subsequent Event [Member] | ||
Payment of plaintiffs | $ 5,000 | |
Vendor [Member] | ||
Contractual Fees | $ 24,339 |
Revenue Recognition (Details Na
Revenue Recognition (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue from Contract with Customer [Abstract] | ||
Revenue | $ 0 | $ 255,346 |
Schedule of Derivative Liabilit
Schedule of Derivative Liability (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||
Derivative liability, beginning balance | $ 3,925,106 | $ 3,529,974 |
Addition of new conversion | 47,620 | |
Conversion of note derivatives | (5,094,792) | |
Change in fair value | (2,478,098) | 5,442,304 |
Derivative liability, ending balance | 1,447,008 | 3,925,106 |
Notes [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Derivative liability, beginning balance | 3,925,101 | 3,529,967 |
Addition of new conversion | 47,620 | |
Conversion of note derivatives | (5,094,792) | |
Change in fair value | (2,478,093) | 5,442,306 |
Derivative liability, ending balance | 1,447,008 | 3,925,101 |
Warrants Derivative [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Derivative liability, beginning balance | 5 | 7 |
Addition of new conversion | ||
Conversion of note derivatives | ||
Change in fair value | (5) | (2) |
Derivative liability, ending balance | $ 5 |
Schedule of Assumptions Used Bl
Schedule of Assumptions Used Black Scholes Valuation of Derivative (Details) - Derivative Liability [Member] | 12 Months Ended |
Dec. 31, 2021$ / shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Stock price at valuation date | $ 0.0002 |
Derivative liability, term | 29 days |
Measurement Input, Risk Free Interest Rate [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Derivative liability, fair value measurement input, percentage | 0.0006 |
Measurement Input, Price Volatility [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Derivative liability, fair value measurement input, percentage | 3.5010 |
Measurement Input, Expected Dividend Rate [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Derivative liability, fair value measurement input, percentage | 0 |
Derivative Valuation (Details N
Derivative Valuation (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Amortized of debt discount | $ 795,591 | |
Derivative Liability [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Amortized of debt discount | $ 0 | $ 619,799 |
Supplemental Cash Flow Inform_2
Supplemental Cash Flow Information (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Dividends Payable [Line Items] | ||
Stock issued during the period for settlement of debt, shares | 16,849,013,669 | |
Stock issued during the period for settlement of debt,value | $ 1,607,317 | |
Accrued interest | 145,167 | |
Financing costs | $ 95,933 | |
Common Stock [Member] | ||
Dividends Payable [Line Items] | ||
Conversion of stock, shares converted | 1,643,200,000 | |
Shares issued during period for services, shares | 2,001,666 | 668,332 |
Shares issued during period for services, value | $ 750 | $ 1,737 |
Series E Preferred Stock [Member] | ||
Dividends Payable [Line Items] | ||
[custom:StockIssuedDuringPeriodSharesNewIssue] | 350,000 | |
[custom:StockIssuedDuringPeriodValueNewIssue] | $ 350,000 | |
[custom:ConversionOfStockShareConverted1] | 163,400 | |
Series E Preferred Stock [Member] | Common Stock [Member] | ||
Dividends Payable [Line Items] | ||
[custom:ConversionsOfStockAmountConverted1] | $ 163,400 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) | Mar. 14, 2022USD ($) |
Former Consultant [Member] | Subsequent Event [Member] | |
Subsequent Event [Line Items] | |
Payment of plaintiffs | $ 38,000 |